OncLive News Network: On Location at ASCO 2021 - Episode 2

Insights in Breast Cancer, GI Malignancies at ASCO 2021: Drs Milind Javle and Erika Hamilton

Gina Mauro
Gina Mauro

Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

,
Erika P. Hamilton, MD, Sarah Cannon Research Institute

,
Milind Javle, MD, MD Anderson Cancer Center

OncLive sits down with Erika P. Hamilton, MD, and Milind Javle, MD, on the pivotal studies in breast cancer and gastrointestinal cancers, respectively, at the 2021 ASCO Annual Meeting.

Today-

We are reporting from the 2021 ASCO Annual Meeting!

We are highlighting some of the top news presented each day during the meeting—and soon we’ll speak with Dr. Milind Javle to highlight the latest in gastrointestinal cancers, and Dr. Erika Hamilton to share her insight on the biggest breast cancer abstracts.

Welcome to OncLive News Network! I’m Gina Mauro.

Data from the phase 2 NIFTY trial demonstrated that liposomal irinotecan in combination with 5-fluorouracil/leucovorin significantly improved progression-free and overall survival for patients with metastatic biliary tract cancer whose disease had progressed following first-line line gemcitabine/cisplatin.

Camrelizumab in combination with chemotherapy demonstrated improved overall and progression-free survival, as well as a manageable safety profile, as a frontline therapy vs placebo/chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma. The data were from the ongoing phase 3 ESCORT-1st trial.

In breast cancer, ribociclib plus fulvestrant continued to significantly improve overall survival over fulvestrant alone in postmenopausal patients with hormone receptor–positive, HER2-negative advanced disease at almost 5 years of follow-up, irrespective of whether patients received the regimen in the first- or second-line setting, as seen in an exploratory analysis of the phase 3 MONALEESA-3 trial.

Similarly, palbociclib plus fulvestrant was found to maintain a clinically meaningful improvement in overall survival compared with placebo plus fulvestrant in patients with HR-positive, HER2-negative advanced breast cancer at a median follow-up of 73.3 months from the phase 3 PALOMA-3 trial.

In the phase 2, single-arm National Cancer Institute-Children’s Oncology Group Pediatric MATCH trial, cohort findings showed that selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway.

Please be sure to check out more of our coverage from the 2021 ASCO Annual Meeting at OncLive.com.

That’s all for today. Catch us tomorrow, where we will sit down with Dr Nick Vogelzang to highlight some pivotal studies in genitourinary cancers, as well as Dr Erin Crane who will share some intriguing perspectives on gynecologic cancers.

Thank you for watching OncLive News Network: On Location, I’m Gina Mauro.